QuantRx, Fieldtests in DOA test manufacturing and distribution pact:
This article was originally published in Clinica
Executive Summary
Drugs-of-abuse (DOA) testing specialists QuantRx Biomedical and Fieldtests have entered a manufacturing and distribution agreement that will see QuantRx exclusively manufacture the Fieldtests ID product line. According to Doylestown, Pennsylvania-based QuantRx, the product line, which is designed to test for narcotic residue, will be available during the second quarter of 2008. The agreement will also see Fieldtests distribute QuantRx's QuikSense DOA products through its sales network. Fieldtests intends to extend the deal to cover QuantRx's RapidSense lateral flow test and OralSense oral fluid collection device when these products become commercially available. Financial details of the deal were not revealed.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.